Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Vivo Induction of T Cell Apoptosis by Alefacept (LFA-3/IgG1 Fusion Protein, Amevive) in Patients With Psoriasis: An Investigator-Initiated, Open-Label, Mechanism of Action Study

NCT00150982 is registered in ClinicalTrials.gov with University of Medicine and Dentistry of New Jersey as lead sponsor.

NCT NCT00150982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00150982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Vivo Induction of T Cell Apoptosis by Alefacept (LFA-3/IgG1 Fusion Protein, Amevive) in Patients With Psoriasis: An Investigator-Initiated, Open-Label, Mechanism of Action Study
Lead sponsor
University of Medicine and Dentistry of New Jersey
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2003
Completion date
February 28, 2005
Enrollment
9
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis